BrightPath Biotherapeutics Co., Ltd.

Tokyo Stock Exchange 4594.T

BrightPath Biotherapeutics Co., Ltd. Price to Earnings Ratio (P/E) on January 27, 2025: -3.05

BrightPath Biotherapeutics Co., Ltd. Price to Earnings Ratio (P/E) is -3.05 on January 27, 2025, a 19.50% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

BrightPath Biotherapeutics Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is -2.90 on January 15, 2025, which is 4.95% above the current Price to Earnings Ratio (P/E).
BrightPath Biotherapeutics Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is -5.14 on August 01, 2024, which is -68.76% below the current Price to Earnings Ratio (P/E).
BrightPath Biotherapeutics Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.73.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Tokyo Stock Exchange: 4594.T

BrightPath Biotherapeutics Co., Ltd.

CEO	Mr. Kenichi Nagai
IPO Date	Oct. 22, 2015
Location	Japan
Headquarters	Kojimachi Central Building
Employees	42
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years